Strong Earnings Report: Recent discussions on X about Travere Therapeutics (TVTX) have centered on the company’s impressive Q3 earnings, with revenue soaring to $164.9 million, a significant jump from last year. Posts highlight a profit of $25.7 million, driven by robust sales of FILSPARI, their lead therapy. Many users are buzzing about the stock hitting a 52-week high following this news.
Analyst Optimism: Sentiment on X also reflects optimism after a major analyst upgraded their price target to $48, citing potential FDA approval for FILSPARI in early 2026. Some discussions note the stock’s rapid price surge, with a few cautioning about overbought conditions. The upcoming regulatory milestone is seen as a key catalyst by many.
CEO Stock Sale: A point of contention on X involves the recent sale of shares by the company’s CEO, totaling around $3.6 million. While some view this as a potential red flag, others argue it’s routine and doesn’t overshadow the positive financials. This topic has sparked varied reactions among users.
Note: This discussion summary was generated from an AI condensation of post data.
Travere Therapeutics Insider Trading Activity
Travere Therapeutics insiders have traded $TVTX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $TVTX stock by insiders over the last 6 months:
- ERIC M DUBE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 3 sales selling 138,924 shares for an estimated $4,036,782.
- ELIZABETH E REED (Chief Legal Officer and GC) has made 0 purchases and 2 sales selling 14,920 shares for an estimated $353,566.
- PETER HEERMA (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 2 sales selling 4,433 shares for an estimated $117,139.
- WILLIAM E. ROTE (Chief Research Officer) sold 3,198 shares for an estimated $67,317
- CHRISTOPHER R. CLINE (CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 2,827 shares for an estimated $56,297.
- JULA INRIG (CHIEF MEDICAL OFFICER) sold 815 shares for an estimated $11,939
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Travere Therapeutics Hedge Fund Activity
We have seen 116 institutional investors add shares of Travere Therapeutics stock to their portfolio, and 108 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 2,767,693 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $40,961,856
- VIKING GLOBAL INVESTORS LP removed 2,601,922 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,508,445
- JANUS HENDERSON GROUP PLC added 2,012,648 shares (+26.7%) to their portfolio in Q2 2025, for an estimated $29,787,190
- STEPHENS INVESTMENT MANAGEMENT GROUP LLC added 1,599,668 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,232,065
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 1,012,988 shares (-34.7%) from their portfolio in Q2 2025, for an estimated $14,992,222
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,009,720 shares (-91.5%) from their portfolio in Q3 2025, for an estimated $24,132,308
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 1,002,092 shares (+inf%) to their portfolio in Q2 2025, for an estimated $14,830,961
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Travere Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $TVTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/31/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/19/2025
- Wells Fargo issued a "Overweight" rating on 09/11/2025
- Scotiabank issued a "Sector Outperform" rating on 08/07/2025
- Wedbush issued a "Outperform" rating on 08/07/2025
- Citigroup issued a "Buy" rating on 06/11/2025
To track analyst ratings and price targets for Travere Therapeutics, check out Quiver Quantitative's $TVTX forecast page.
Travere Therapeutics Price Targets
Multiple analysts have issued price targets for $TVTX recently. We have seen 8 analysts offer price targets for $TVTX in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Tyler Van Buren from TD Cowen set a target price of $40.0 on 10/31/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $47.0 on 09/19/2025
- Alex Thompson from Stifel set a target price of $25.0 on 09/12/2025
- Mohit Bansal from Wells Fargo set a target price of $35.0 on 09/11/2025
- Laura Chico from Wedbush set a target price of $32.0 on 08/07/2025
- Greg Harrison from Scotiabank set a target price of $31.0 on 08/07/2025
- Carly Kenselaar from Citigroup set a target price of $32.0 on 06/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
